CHARM Therapeutics

Charm Therapeutics is an AI-driven drug discovery company using deep learning to design highly potent small molecule medicines. Founded by leaders with a track record in AI and drug discovery, the company applies its proprietary protein-ligand interaction platform to engineer structurally optimized inhibitors. Charm's lead program focuses on next-generation menin inhibitors for Acute Myeloid Leukemia (AML) — designed to overcome treatment resistance observed in first-generation therapies by reprogramming leukemic cells rather than simply killing them. Headquartered in London with a research presence at the Babraham Research Campus in Cambridge, Charm is advancing its pipeline toward clinical-stage validation.